Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Inhibitor
MMV674850 is a potent inhibitor targeting asexual stage parasites, exhibiting IC50 values of 2.7 and 4.5 nM. This compound preferentially affects early-stage gametocytes, with an IC50 of 4.5 ± 3.6 nM, while late-stage gametocytes display an IC50 of 28.7 ± 0.2 nM. MMV674850 serves as a valuable tool for research focused on malaria and parasite biology, particularly in investigating gametocyte development and inhibition strategies. -
Parasite Inhibitor
PfPKG-IN-1 is an imidazole-based inhibitor targeting Plasmodium falciparum cGMP-dependent protein kinase (PfPKG). This compound exhibits significant biological activity by interfering with the function of PfPKG, an essential enzyme in the life cycle of the malaria parasite. PfPKG-IN-1 is utilized in research applications aimed at developing effective antimalarial therapies and understanding the molecular mechanisms of parasite survival and replication. -
Parasite Inhibitor
6-Benzylthioinosine acts as a potent inhibitor of parasite growth, demonstrating significant antileukemic activity by enhancing cytotoxic effects against acute myeloid leukemia cells. It operates by modulating cellular metabolism and influencing signaling pathways, particularly when used in combination with metformin. This compound is valuable for research applications focused on leukemia treatment and understanding metabolic regulation in cancer. -
Parasite Inhibitor
Antileishmanial agent-2 is a potent inhibitor targeting Leishmania parasites, demonstrating submicromolar antileishmanial activity with an IC50 value of 0.29 μM. This compound exhibits a high selectivity index, indicating minimal toxicity to mammalian cells. It is suitable for research applications focused on the development of therapies for leishmaniasis and related parasitic infections. -
Parasite Inhibitor
(+)-Isopulegol functions primarily as a parasite inhibitor, derived from the terpenoid constituents of Mentha canadensis L. It exhibits phagostimulatory effects on adult pests, particularly S. granarius and T. confusum, acting as a feeding attractant for adult T. confusum and larvae of T. granarium. This compound is valuable for research applications in pest control and management strategies targeting stored product insects. -
Parasite Inhibitor
SLU-10906 is a potent inhibitor targeting the protozoan parasite Cryptosporidium. Demonstrating significant efficacy in a cell-based infection model with an EC50 of 0.19 μM, SLU-10906 is non-cytotoxic, making it a valuable tool for investigating cryptosporidiosis. Its oral bioavailability further enhances its potential for preclinical studies and therapeutic exploration. -
Parasite Inhibitor
Carbonic anhydrase inhibitor 27 is a targeted antitrypanosomal agent that inhibits carbonic anhydrase activity, impacting parasite viability. This compound effectively reduces parasitic load in the bloodstream and enhances the survival rate of infected murine models. It is valuable for research applications focused on the treatment of parasitic infections such as Trypanosomiasis. -
Parasite Inhibitor
MMV665852 is an antischistosomal agent that targets Schistosoma mansoni, inhibiting worm viability in vitro. This compound has demonstrated efficacy in reducing worm burden in murine models of schistosomiasis, making it a valuable tool for research in parasitic disease treatment and prevention. -
Inhibitor of Parasite Motility and Invasion
TachypleginA-2 is a small-molecule inhibitor that targets parasite motility and invasion. It effectively induces a mobility shift in TgMLC1, an essential light chain involved in cellular movement. This compound is useful for research investigating the mechanisms of parasitic behavior and the development of potential therapeutic strategies against parasitic infections. -
Parasite Inhibitor
Bitipazone is a potent cysteine ester derivative that serves as an effective anticoccidial agent. It demonstrates significant efficacy against coccidian parasites in animal models, including rabbits and turkeys, with good tolerability observed at concentrations below 90 ppm in feed. Pharmacokinetic studies indicate that Bitipazone is slowly eliminated from the blood and organs, making it a valuable compound for research in parasitology and veterinary medicine. -
Parasite Inhibitor
AB 3217-B is a parasite inhibitor that targets mite species with potent anti-mite activity. This compound demonstrates efficacy in disrupting the life cycle of parasites, making it valuable for research related to pest control and parasitology. Its ability to inhibit mite proliferation positions it as a potential candidate for further studies aimed at developing effective treatments against parasitic infestations. -
Parasite Inhibitor
Anti-Trypanosoma cruzi agent-5 is a potent inhibitor of Trypanosoma cruzi, the causative agent of Chagas disease. This compound demonstrates significant antiparasitic activity, inhibiting the proliferation of the parasite in vitro. It is suitable for research applications investigating the mechanisms of Chagas disease and potential therapeutic strategies. -
Parasite Inhibitor
RS 49676 is an N-substituted imidazole compound that acts as a potent inhibitor against endogenous amoebae, displaying an ED50 of less than 0.1 ng/mL. It demonstrates significant biological activity in vivo, notably prolonging the average survival time of mice infected with Trypanosoma cruzi to over 11 weeks when administered at a dose of 100 mg/kg per day via subcutaneous injection. This compound is valuable for research applications involving parasitic infections and host-pathogen interactions. -
Parasite Tyrosyl-tRNA Synthetase Inhibitor
ML471 is an orally active inhibitor of parasite tyrosyl-tRNA synthetase (PfTyrRS), which is essential for protein synthesis in Plasmodium species. This compound exhibits potent activity against malaria by selectively targeting PfTyrRS, providing valuable insights into the treatment of malaria infections. It is a useful tool for researchers investigating novel antimalarial strategies and exploring the role of tRNA synthetases in parasitic biology. -
Parasite Inhibitor
(Rac)-ACT-451840 is a parasite inhibitor with significant antimalarial properties. It demonstrates effective antimalarial activity against P. berghei-infected mice, achieving an ED90 of 13 mg/kg and showing inhibitory effects at higher doses. In humanized immunodeficient mouse models infected with P. falciparum, the compound has an ED90 of 3.7 mg/kg. (Rac)-ACT-451840 is structurally similar to artemisinin and offers a rapid onset of action, although it necessitates repeated high dosing for optimal efficacy. -
Parasite Inhibitor
WRR-483 is an irreversible cysteine protease inhibitor targeting cruzain, demonstrating potent trypanocidal activity against Trypanosoma cruzi. This compound effectively inhibits the proliferation of the parasite in cell culture and shows significant efficacy in eradicating parasitic infection in acute Chagas disease mouse models. Its pH-dependent high affinity makes WRR-483 a promising candidate for research applications focused on combating Chagas disease. -
Reverse Transcriptase Inhibitor
5'-Azido-5'-deoxythymidine is a nucleoside analogue that functions as an inhibitor of reverse transcriptase. By mimicking natural nucleosides, it integrates into viral DNA during replication, thereby terminating chain elongation and effectively inhibiting viral propagation. This compound is valuable for research into retroviral infections, including AIDS, contributing to the understanding and treatment of these diseases. -
reverse transcriptase inhibitor
Depulfavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates exceptional antiviral activity with an IC50 of 1.1 nM against wild-type HIV-1 and maintains effectiveness (IC50 < 100 nM) against 92% of various NNRTI-resistant clinical isolates. This compound is valuable for research into HIV resistance mechanisms and the development of novel antiviral therapies. -
AMV Reverse Transcriptase Inhibitor
Limocrocin is an inhibitor of avian myeloid leukemia virus (AMV) reverse transcriptase. This compound, derived from Streptomyces limosus, exhibits significant inhibitory activity independent of variations in template-primer concentration, substrate, or carrier protein levels. However, its efficacy diminishes with increasing concentrations of AMV reverse transcriptase. Limocrocin serves as a valuable tool for research in antiviral treatment development. -
Non-nucleoside Reverse Transcriptase Inhibitor
(R)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts through non-competitive inhibition of the viral enzyme. It is selectively metabolized by CYP2B6 to form 8-hydroxyefavirenz, which highlights its potential as a probe for studying the CYP2B6 active site and its catalytic mechanisms. This compound serves as a valuable tool in the research of antiviral therapeutics and the pharmacokinetics of HIV treatment. -
Reverse Transcriptase Inhibitor
Trovirdine hydrochloride is an HIV reverse transcriptase inhibitor, acting as a non-nucleoside inhibitor (NNI) of the enzyme. It demonstrates significant biological activity against HIV replication, effectively achieving inhibition at nanomolar concentrations without cytotoxic effects in infected peripheral blood mononuclear cells. This compound serves as a valuable tool for research applications focused on understanding HIV therapeutics and developing more potent derivatives for enhancing antiviral strategies. -
Reverse Transcriptase Inhibitor
Mniopetal E is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by interfering with the reverse transcription process, making it valuable for research in viral replication studies and the development of antiviral therapies. Its selective inhibition of reverse transcriptase may also provide insights into nucleic acid synthesis mechanisms in various biological systems. -
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
RSV Fusion Glycoprotein Inhibitor
CGR-50 is a selective inhibitor of the respiratory syncytial virus (RSV) fusion glycoprotein, demonstrating potent activity with an EC50 of 32.6 nM against RSV A2 in HEp-2 cell lines. This compound effectively blocks RSV entry by binding to the F protein, thereby inhibiting the critical process of membrane fusion. CGR-50 is a valuable tool for research dedicated to understanding and combating RSV infections. -
RSV-F Protein Inhibitor
Sisunatovir is a potent inhibitor of the respiratory syncytial virus (RSV), targeting the RSV-F protein with IC50 values of 1.4 nM and 1.0 nM for RSV A and RSV B, respectively. It effectively inhibits RSV infection and has demonstrated the ability to reduce viral titers in the lungs of murine models. This compound is valuable for research applications focused on developing therapeutic strategies against RSV infections. -
RSV Inhibitor
Zelicapavir is an orally active inhibitor of respiratory syncytial virus (RSV) specifically targeting the viral replication process. With an effective concentration (EC50) of less than 0.4 μM, it demonstrates potent antiviral activity. This compound is applicable in research focused on understanding RSV pathogenesis and developing therapeutic strategies against RSV infections. -
RSV Inhibitor
4-Methoxycinnamaldehyde is an RSV inhibitor known for its cytoprotective activity against respiratory syncytial virus. This compound demonstrates significant efficacy in human larynx carcinoma cell lines, effectively inhibiting RSV-induced cytopathic effects with an estimated IC50 value of 0.055 μg/mL. Its properties make it a valuable tool for research into antiviral therapies and understanding RSV pathogenesis. -
RSV Inhibitor
BMS-433771 is a potent orally active inhibitor targeting respiratory syncytial virus (RSV). It demonstrates efficacy against both RSV A and B strains, with an average EC50 value of 20 nM. This compound is a valuable tool for research on respiratory tract diseases, aiding in the understanding of RSV pathology and potential therapeutic interventions. -
RSV Inhibitor
VP-14637 is a novel respiratory syncytial virus (RSV) fusion inhibitor that demonstrates potent antiviral activity with an IC50 of 1.42 ng/mL. This compound specifically targets the fusion process of RSV, making it a valuable tool for studying viral entry mechanisms and evaluating potential therapeutic strategies against RSV infections. Its high efficacy positions VP-14637 as an important reagent for researchers working on respiratory viral diseases. -
RSV Inhibitor
RSV L-protein-IN-1 is a potent inhibitor of Respiratory Syncytial Virus (RSV) that targets viral polymerase with an IC50 of 0.089 μM. It effectively disrupts RSV mRNA synthesis by inhibiting the guanylation of viral transcripts, demonstrating an EC50 of 0.021 μM. In addition to its antiviral activity, RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM in HEp-2 cells) and has been shown to lower virus titers in mouse models of RSV infection, making it suitable for research applications aimed at understanding RSV pathogenesis and developing therapeutic strategies. -
RSV Inhibitor
JNJ 2408068 is a potent inhibitor of respiratory syncytial virus (RSV). This compound effectively suppresses the replication of RSV A and B subtypes in pulmonary tissue, demonstrating significant antiviral activity without observable toxicity in vivo. Its minimum protective dose is approximately 0.39 mg/kg, making it a valuable tool for research into RSV pathogenesis and therapeutic interventions. -
RSV Inhibitor
3,4-Di-O-caffeoyl quinic acid methyl ester is a dicaffeoyl derivative that acts as an inhibitor of respiratory syncytial virus (RSV). It demonstrates significant antiviral activity against RSV, with an IC50 value of 0.78 μg/mL. This compound is useful for research applications focused on RSV-related infections and exploring potential therapeutic options. -
RSV Inhibitor
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), exhibiting an IC50 of 50 nM. This compound disrupts the binding and fusion processes of the virus by targeting the viral fusion protein. RFI-641 serves as a valuable tool in RSV research, aiding studies on viral replication mechanisms and the development of therapeutic strategies against RSV infections. -
hRSV Inhibitor
hRSV-IN-1 is a potent inhibitor of the human respiratory syncytial virus (hRSV), acting primarily by interfering with viral replication. This compound exhibits significant antiviral activity, making it an important tool for research in hRSV pathogenesis and treatment strategies. hRSV-IN-1 is particularly valuable for studies focusing on respiratory viral infections and the development of therapeutic interventions. -
RSV Polymerase inhibitor
RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV. -
RSV Inhibitor
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV), demonstrating an EC50 of 0.1 μM. This compound primarily targets the RSV polymerase, with an IC50 of 0.66 μM, effectively blocking mRNA synthesis by inhibiting the guanylation of viral transcripts. Despite exhibiting moderate cytotoxicity (CC50 of 10.7 μM in HEp-2 cells), RSV L-protein-IN-5 shows significant antiviral activity in preclinical mouse models of RSV infection, making it a valuable tool for RSV research and therapeutic development. -
RSV Inhibitor
RSV-IN-5 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) fusion proteins, effective against both wild-type and mutant strains. This compound demonstrates significant anti-RSV activity, with an EC50 of 2.0 nM against the wild-type A2 F protein and 8.1 nM against the D486N-mutant F protein. Its efficacy makes RSV-IN-5 a valuable tool in research focused on RSV-related therapeutics and understanding viral resistance mechanisms. -
RSV Inhibitor
Genkwanol C is a biflavonoid that serves as an inhibitor of respiratory syncytial virus (RSV). It demonstrates potent antiviral activity against RSV in vitro, making it a valuable tool for research on viral infections and potential therapeutic applications. Its mechanism of action offers insights into the interaction between flavonoids and viral pathogens. -
RSV Inhibitor
ent-11β-Hydroxyatis-16-ene-3,14-dione is a diterpenoid derived from the fresh roots of Euphorbia jolkinii, primarily targeting respiratory syncytial virus (RSV). This compound exhibits significant anti-RSV activity, making it a valuable tool for research in viral pathogenesis and therapeutic development focused on respiratory viral infections. Its role in inhibiting RSV positions it as a potential candidate for further exploration in antiviral research. -
RSV Polymerase Inhibitor
RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections. -
RSV Inhibitor
TP0591816 is a highly potent dual inhibitor targeting both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins, exhibiting effective inhibition with EC50 values of 0.27 nM for wild-type and 0.70 nM for the D486N mutant. This compound demonstrates significant antiviral activity, making it a valuable tool for RSV research and potential therapeutic development. Researchers can utilize TP0591816 to explore mechanisms of RSV pathogenesis and evaluate antiviral strategies against this respiratory virus. -
RSV Inhibitor
BMS-433771 dihydrochloride hydrate is a selective inhibitor of respiratory syncytial virus (RSV), effectively targeting both RSV A and B strains. With an average EC50 of 20 nM, it demonstrates significant antiviral activity. This compound is valuable for research applications focused on respiratory tract diseases and the mechanisms underlying RSV infection and pathogenesis. -
RSV Polymerase Inhibitor
RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms. -
RSV Inhibitor
BTA-9881 is a potent respiratory syncytial virus (RSV) inhibitor, demonstrating EC50 values of 48 nM, 59 nM, and 160 nM against RSV A2, RSV Long, and RSV B1, respectively. Its favorable pharmacokinetic properties make it a valuable reagent for studying RSV infection and evaluating potential antiviral therapies. BTA-9881 serves as an important tool in respiratory virus research, aiding in the development of effective treatments for RSV-related diseases. -
RSV Inhibitor
JNJ-7184 is a non-nucleoside inhibitor targeting the RSV-Large (L) polymerase. This compound exhibits potent antiviral activity, demonstrating a pEC50 of 7.86 and a pCC50 of 4.29 in HeLa cells. JNJ-7184 effectively prevents respiratory syncytial virus (RSV) replication and transcription by disrupting the initiation and early elongation stages of the viral life cycle, making it a valuable tool for research into RSV pathogenesis and potential therapeutic strategies.
